ATS Highlights

Dr. Ian Pavord and Dr. Simon Couillard, ATS 2021: The ORACLE Scale for the Prediction of Asthma Attacks

We had the great pleasure to meet with Dr. Ian Pavord (University of Oxford, Oxford, UK) and Dr. Simon Couillard (University of Oxford, Oxford, UK and University of Sherbrooke, Sherbrooke, Canada) to learn about the OxfoRd Asthma attaCk risk ScaLE (ORACLE), a proof-of-concept scale to predict asthma attacks. You can view the prototype Oxford Asthma […]

Asthma

Dr. Ian Pavord and Dr. Simon Couillard, ATS 2021: The OxfoRd Asthma attaCk risk ScaLE (ORACLE)

Idiopathic pulmonary fibrosis

Rebecca Bascom, ATS 2021: MN-001 in Idiopathic Pulmonary Fibrosis

We were delighted to talk with Dr Rebecca Bascom (Penn State Hershey Medical Center, Hershey, PA, US) around her study investigating the use of MN-001 in patients with idiopathic pulmonary fibrosis. ‘A Single-Center, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of MN-001 (Tipelukast) in Subjects with Idiopathic Pulmonary Fibrosis.‘ was presented at […]

COPD

Douglas Mapel, ATS 2021: The Rate of ED Visits in Patients with COPD in the IMPACT Trial

It was a pleasure to meet with Dr Douglas Mapel (Northern Arizona Pulmonary Associates – Critical Care, Flagstaff, AZ, US) to talk around his abstract on ‘Reduction in Emergency Department (ED) Visits in Patients with Chronic Obstructive Pulmonary Disease (COPD): Analysis of the IMPACT Trial.‘, which was presented at ATS 2021 International Conference, 14-19 May, […]

Respiratory Distress Syndrome

Wayne Anderson, ATS 2021: BIO‑11006 in Patients with Acute Respiratory Distress Syndrome

It was a pleasure to meet with Dr Wayne Anderson (UNC School of Medicine, Chapel Hill, NC, US) to discuss his recent study evaluating the safety and tolerability of BIO‑11006 in patients with acute respiratory distress syndrome. ‘A Phase II, Placebo‑Controlled, Multicenter Pilot Study to Evaluate the Safety and Efficacy of BIO‑11006 Inhalation Solution in […]

Respiratory Distress Syndrome

Wayne Anderson, ATS 2021: Targeting the MARCKS Protein in Respiratory Disease

Asthma

Andrew Menzies-Gow, ATS 2021: Tezepelumab in Oral Corticosteroid-Dependent Patients with Severe Asthma

It was a pleasure to talk to Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College, London, UK) around his recent analysis of the NAVIGATOR data, investigating the effect of tezepelumab in OCS-dependent severe asthma patients (Clinical Trial Identifier: NCT03347279). The abstract ‘Effect of Tezepelumab in Oral Corticosteroid-Dependent Patients with Severe Asthma: Results From the […]

Chronic Cough

Jacky Smith, ATS 2021: Findings from the COUGH-1 and COUGH-2 Study Data

We were delighted to talk with Professor Jacky Smith (School of Biological Sciences, The University of Manchester, Manchester, UK) around cough frequency with gefapixant in patients with chronic cough. The abstract ‘Objective Cough Frequency with Gefapixant in Chronic Cough: A Pooled Analysis of Two Phase 3 Randomized, Controlled Clinical Trials (COUGH-1 and COUGH-2).’ was presented […]

COVID-19

Sara Tomassetti, ATS 2021: Post-COVID-19 Interstitial Lung Syndrome

We were delighted to catch up with Dr Sara Tomassetti (Careggi University Hospital, Florence, Italy) around interstitial lung changes following SARS-CoV-2 infection. The abstract ‘A Multidisciplinary Multicenter Study Evaluating Risk Factors, Prevalence and Characteristics of Post-COVID-19 Interstitial Lung Syndrome PCOILS.‘ (ABSTRACT NUMBER: A1748) was presented at ATS 2021 International Conference, 14-19 May, 2021. Questions What […]

FILTER YOUR SEARCH

Speciality:

ATS Highlights

Dr. Ian Pavord and Dr. Simon Couillard, ATS 2021: The ORACLE Scale for the Prediction of Asthma Attacks

Dr. Ian Pavord and Dr. Simon Couillard, ATS 2021: The OxfoRd Asthma attaCk risk ScaLE (ORACLE)

Rebecca Bascom, ATS 2021: MN-001 in Idiopathic Pulmonary Fibrosis

Douglas Mapel, ATS 2021: The Rate of ED Visits in Patients with COPD in the IMPACT Trial

Wayne Anderson, ATS 2021: BIO‑11006 in Patients with Acute Respiratory Distress Syndrome

Wayne Anderson, ATS 2021: Targeting the MARCKS Protein in Respiratory Disease

Andrew Menzies-Gow, ATS 2021: Tezepelumab in Oral Corticosteroid-Dependent Patients with Severe Asthma

Jacky Smith, ATS 2021: Findings from the COUGH-1 and COUGH-2 Study Data

Sara Tomassetti, ATS 2021: Post-COVID-19 Interstitial Lung Syndrome

Journal articles and more to your inbox

FILTER YOUR SEARCH

Speciality:

ATS Highlights

Dr. Ian Pavord and Dr. Simon Couillard, ATS 2021: The ORACLE Scale for the Prediction of Asthma Attacks

Dr. Ian Pavord and Dr. Simon Couillard, ATS 2021: The OxfoRd Asthma attaCk risk ScaLE (ORACLE)

Rebecca Bascom, ATS 2021: MN-001 in Idiopathic Pulmonary Fibrosis

Douglas Mapel, ATS 2021: The Rate of ED Visits in Patients with COPD in the IMPACT Trial

Wayne Anderson, ATS 2021: BIO­‑11006 in Patients with Acute Respiratory Distress Syndrome

Wayne Anderson, ATS 2021: Targeting the MARCKS Protein in Respiratory Disease

Andrew Menzies-Gow, ATS 2021: Tezepelumab in Oral Corticosteroid-Dependent Patients with Severe Asthma

Jacky Smith, ATS 2021: Findings from the COUGH-1 and COUGH-2 Study Data

Sara Tomassetti, ATS 2021: Post-COVID-19 Interstitial Lung Syndrome

Journal articles and more to your inbox

Wayne Anderson, ATS 2021: BIO‑11006 in Patients with Acute Respiratory Distress Syndrome